The COOL-AF Phase 2 Registry: COhort of Antithrombotic Use and Clinical Outcomes in Atrial Fibrillation Patients.
Rungroj Krittayaphong, Arjbordin Winijkul, Voravut Rungpradubvong...
https://pubmed.ncbi.nlm.nih.gov/39896253/Actively Recruiting
Led by Mahidol University · Updated on 2025-05-09
4000
Participants Needed
33
Research Sites
52 weeks
Total Duration
Atrial fibrillation AF is a major cause of heart-related illness and death, especially among Asian patients who face higher risks of serious bleeding such as brain hemorrhage compared to non-Asians. This research, called the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation COOL-AF Phase 2, aims to study how antithrombotic medication use changes over time and how these changes affect health outcomes in people with AF. The study is observational and conducted across multiple centers in Thailand. Participants in this study have known or newly diagnosed non-valvular AF and are followed without any intervention or treatment assigned by the study. The study plans to enroll about 3680 patients over two years from 33 centers. Participants will be monitored every 6 months for up to 3 years to observe patterns of medication use, particularly warfarin and non-vitamin K antagonist oral anticoagulants NOACs, and clinical events including stroke, systemic embolism, bleeding, heart attacks, and heart failure. Throughout the study, patients will have regular check-ins every six months to track their medication usage and health status. Researchers will collect data on important outcomes such as rates of stroke, bleeding events, and quality of life. The studys primary focus is on long-term safety and effectiveness of antithrombotic treatments in this population. The total participation duration can be up to 3 years, ensuring thorough observation of clinical outcomes and treatment patterns.
CONDITIONS
COhort of antithrOmbotic Use and cLinical Outcomes in Patients With Atrial Fibrillation (COOL-AF) Phase 2
P
Pontawee Kaewcomdee, B.N.S
R
Rungroj Krittayaphong, MD,FESC,FACC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mahidol University
Lead Sponsor
Health Systems Research Institute,Thailand
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants diagnosed with atrial fibrillation are observed over time without any intervention to monitor clinical outcomes.
Periodic visits over 3 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Rungroj Krittayaphong, Arjbordin Winijkul, Voravut Rungpradubvong...
https://pubmed.ncbi.nlm.nih.gov/39896253/Mahidol University
Lead Sponsor
Health Systems Research Institute,Thailand
Collaborating Sponsor